Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1078 - 1084
Section I - De la conception à la production
Published online 15 December 2009
  1. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30. [Google Scholar]
  2. Scolnik P. mAbs: a business perspective. mAbs 2009; 1 : 1–6. [Google Scholar]
  3. Reichert J. Number of mAbs entering clinical study nearly tripled in last decade. Tufts Center for Study of Drug Development Impact Report 2008; 10 :1–4. [Google Scholar]
  4. Werner R. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol 2004; 113 : 171–82. [Google Scholar]
  5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7. [Google Scholar]
  6. Roskos L, Davis C, Schwab G. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004; 61 : 108–20. [Google Scholar]
  7. Jones D, Kroos N, Anema R, et al. High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 2003; 19 : 163–8. [Google Scholar]
  8. Yallop C, Raamsman M, Zuijderwijk M, et al. High level production of recombinant IgG in the human cell line PER.C6. In : Francesc Gòdia MF, ed. Animal cell technology meets genomics. Amsterdam : Springer Netherlands, 2005 : 533–6. [Google Scholar]
  9. Gurramkonda C, Adnan A, Gabel T, et al. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: application to intracellular production of Hepatitis B surface antigen. Microb Cell Fact 2009; 8 :13. [Google Scholar]
  10. Barnes LM, Dickson AJ. Mammalian cell factories for efficient and stable protein expression. Curr Opin Biotechnol 2006; 17 : 381–6. [Google Scholar]
  11. Kwaks TH, Otte AP. Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells. Trends Biotechnol 2006; 24 : 137–42. [Google Scholar]
  12. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6 : 343–57. [Google Scholar]
  13. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276 : 6591–604. [Google Scholar]
  14. Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23 : 1283–8. [Google Scholar]
  15. Lim SF, Chuan KH, Liu S, et al. RNAi suppression of Bax and Bak enhances viability in fed-batch cultures of CHO cells. Metab Eng 2006; 8 : 509–22. [Google Scholar]
  16. Sung YH, Hwang SJ, Lee GM. Influence of down-regulation of caspase-3 by siRNAs on sodium-butyrate-induced apoptotic cell death of Chinese hamster ovary cells producing thrombopoietin. Metab Eng 2005; 7 : 457–66. [Google Scholar]
  17. Figueroa B Jr, Sauerwald TM, Mastrangelo AJ, et al. Comparison of Bcl-2 to a Bcl-2 deletion mutant for mammalian cells exposed to culture insults. Biotechnol Bioeng 2001; 73 : 211–22. [Google Scholar]
  18. Chiang GG, Sisk WP. Bcl-x(L) mediates increased production of humanized monoclonal antibodies in Chinese hamster ovary cells. Biotechnol Bioeng 2005; 91 : 779–92. [Google Scholar]
  19. Borth N, Mattanovich D, Kunert R, et al. Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line. Biotechnol Prog 2005; 21 : 106–11. [Google Scholar]
  20. Davis R, Schooley K, Rasmussen B, et al. Effect of PDI overexpression on recombinant protein secretion in CHO cells. Biotechnol Prog 2000; 16 : 736–43. [Google Scholar]
  21. Bergemann K, Eckermann C, Garidel P, et al. Production and downstream processing. In : Dübel S, ed. Handbook of therapeutic antibodies. New York : Wiley, 2007 : 199–237. [Google Scholar]
  22. Foulon A, Trach F, Pralong A, et al. Using disposables in an antibody production process. BioProcess Int 2008; 6 : 12–7. [Google Scholar]
  23. The single-use technology guidebook. BioProcess Int 2008; 6 (suppl 3). [Google Scholar]
  24. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008; 9 : 447–67. [Google Scholar]
  25. Scott C. Proactive debottlenecking. Planning ahead for the downstream bottleneck. BioProcess Int 2008; 6 : 32–42. [Google Scholar]
  26. Arunakumari A, Wang J, Figueroa B Jr. Advances in non-protein A purification processes for human monoclonal antibodies. Biopharm Int 2009 (suppl mars). [Google Scholar]
  27. Seaman C, Fries S, Beck A, et al. Cell cultivation process transfer and scale-up. In support of production of early clinical supplies of an anti IGF-1R antibody (part 1). BioProcess Int 2008; 6 : 26–36. [Google Scholar]
  28. Seaman C, Fries S, Beck A, et al. Cell cultivation process transfer and scale-up. In support of production of early clinical supplies of an anti IGF-1R antibody (part 2). BioProcess Int 2008; 6 : 34–42. [Google Scholar]
  29. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9 : 482–501. [Google Scholar]
  30. Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848 : 8–18. [Google Scholar]
  31. Faye L, Champey Y. Plants, medicine and genetics, which applications for tomorrow ? Med Sci (Paris) 2008; 24 : 939–45. [Google Scholar]
  32. Cadoret JP, Bardor M, Lerouge P, et al. Microalgae as cell factories producing recombinant commercial proteins. Med Sci (Paris) 2008; 24 : 375–82. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.